The most successful mouse model to date uses albumin promoter-urokinase-type plasminogen activator (Alb-uPA)-transgenic mice that overexpress uPA in the liver which results in hypofibrinogenemia, neonatal bleeding and progressive liver degeneration [1]. Here, ALB is linked to Hypofibrinogenemia.